ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 145 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,869,191 | -44.3% | 1,105,309 | 0.0% | 2.34% | -32.6% |
| Q2 2023 | $10,533,595 | +68.3% | 1,105,309 | +94.2% | 3.47% | +34.7% |
| Q1 2023 | $6,259,451 | -25.7% | 569,041 | 0.0% | 2.58% | -29.6% |
| Q4 2022 | $8,421,807 | -22.6% | 569,041 | 0.0% | 3.66% | -7.9% |
| Q3 2022 | $10,874,000 | -10.3% | 569,041 | 0.0% | 3.97% | -34.9% |
| Q2 2022 | $12,126,000 | +10.6% | 569,041 | 0.0% | 6.11% | +17.8% |
| Q1 2022 | $10,960,000 | -7.1% | 569,041 | 0.0% | 5.19% | +5.1% |
| Q4 2021 | $11,802,000 | -13.2% | 569,041 | 0.0% | 4.94% | +2.7% |
| Q3 2021 | $13,594,000 | -12.5% | 569,041 | 0.0% | 4.80% | -21.5% |
| Q2 2021 | $15,529,000 | -5.7% | 569,041 | 0.0% | 6.12% | +15.9% |
| Q1 2021 | $16,462,000 | -12.9% | 569,041 | -15.3% | 5.28% | -15.2% |
| Q4 2020 | $18,895,000 | – | 671,716 | – | 6.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |